Pfizer expects $59.5B-$62.5B 2026 revenue, cites post-2028 high single-digit CAGR visibility after Vyndamax settlement (NYSE:PFE)
辉瑞辉瑞(US:PFE) Seeking Alpha·2026-05-06 02:03

技术访问问题 - 用户需在浏览器中启用Javascript和cookies以正常访问内容 [1] - 启用广告拦截器可能导致访问受阻，需禁用广告拦截器并刷新页面 [1]

Pfizer expects $59.5B-$62.5B 2026 revenue, cites post-2028 high single-digit CAGR visibility after Vyndamax settlement (NYSE:PFE) - Reportify